Inclusion Criteria:

          1. Male or female ≥18 years of age

          2. Subject must have an advanced solid tumor

          3. ECOG Performance Status of 0 or 1

          4. Life expectancy ≥12 weeks

          5. Adequate laboratory parameters

          6. Female subjects agree not to be pregnant or lactating from beginning of the study
             screening until 4 months after receiving the last treatment; Male and female subjects
             and their sexual partners are willing and able to employ a highly effective method of
             birth control/contraception.

          7. Willing and able to comply with clinic visits and study-related procedures

          8. Provide signed informed consent

        Exclusion Criteria:

          1. Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products

          2. Any concurrent therapy for cancer, radiation, or surgery within 4 weeks, except for
             minor palliative intent (this is to be discussed with sponsor)

          3. Any concurrent use of anti-infective, anti-fungal, or anti-viral agent (exceptions are
             to be approved by the sponsor)

          4. Any other prohibited or restricted medication as described in the study protocol.

          5. Investigational therapy administered <5 half-lives before the first dose of HTI-1066

          6. Any anticancer therapy administered <5 half-lives before first dose of HTI-1066; any
             prior immune-oncology products administered within 4 weeks or 5 half-lives before the
             first dose of HTI-1066 as described above; or surgery or radiotherapy administered
             within 4 weeks before the first dose of HTI-1066.

          7. Active CNS metastases.

          8. Cardiac disease (NYHA classes II-IV) including myocardial infarction within 6 months
             before enrollment, or unstable angina, congestive heart failure, or cardiac arrhythmia
             requiring treatment.

          9. History or presence of an abnormal ECG, ECHO, or MUGA that is clinically meaningful.

         10. History of immunodeficiency including seropositivity for human immunodeficiency virus
             (HIV), or other acquired or congenital immune-deficient disease, or any active
             systemic viral infection requiring therapy (e.g., hepatitis B or C)

         11. Any other medical, psychiatric, or social condition deemed by the investigator to be
             likely to interfere with a subject's rights, safety, welfare or ability to sign
             informed consent, cooperate and participate in the study, or interfere with the
             interpretation of the results

         12. Active infection or an unexplained fever >38.5°C during Screening or on the first
             scheduled day of dosing.

         13. Unresolved toxicities from previous anticancer therapy.